Auliac JB, Guisier F, Bizieux A, et al. - In advanced non-small–cell lung cancer (NSCLC) patients, researchers conducted this prospective, multicenter study, researchers sought to determine the prognostic ability of tumor-cell (TC) and immune-cell (IC) PD-L1 expressions. Participants were advanced NSCLC cases with performance status 0/1. The estimated first-, second- and third-line median (95% CI) progression-free survival (PFS) was 4.6 (3.6– 5.2), 3.7 (2.3– 4.7) and 2.2 (1.5– 4.3) months, respectively, among 198 patients screened in 19 centers; median overall survival (OS) was estimated to be 16.9 (11.4– 19.9) months. Based on TC or IC PD-L1 expression, there existed no significant PFS and OS disparities. Overall, in chemotherapy-treated advanced NSCLC patients, neither TC nor IC PD-L1 expression seemed to be prognostic.